Payment overview · 2025
General Payments
$2,339.62
101 reported records · 29 companies
Healthcare provider profile · identity verified
Manuela Mendes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FALL RIVER, MA · NPI 1912904988
Verified facts
What the public records show
CMS Open Payments records show Manuela Mendes, M.D. received $2,339.62 in general payments during 2025 across 101 reported records.
ABBVIE INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $441.10 | 18.9% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $282.09 | 12.1% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $171.86 | 7.3% | 8 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $148.94 | 6.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.85 | 6.2% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $121.15 | 5.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.30 | 4.8% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $92.23 | 3.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.91 | 3.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.42 | 3.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $65.74 | 2.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.03 | 2.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.65 | 2.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.62 | 2.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $44.75 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.62 | 1.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.81 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.67 | 1.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.23 | 1.4% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $29.61 | 1.3% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $24.19 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.36 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.03 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.94 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.54 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.99 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.45 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.36 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.18 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,339.62 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $269.38 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $222.14 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $171.86 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $148.94 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $139.94 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $121.15 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $117.46 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.27 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.91 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.23 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $86.89 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.09 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $48.81 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $46.34 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.94 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 263 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 171 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 222 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 145 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 223 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 223 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
145 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
222 | 57 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
263 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
222 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
284 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
223 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
223 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
263 | 54 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 997 | 271 |
| Lisinopril | Lisinopril | 740 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 202 |
| Pantoprazole Sodium | Pantoprazole Sodium | 665 | 203 |
| Levothyroxine Sodium | Levothyroxine Sodium | 614 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 606 | 151 |
| Montelukast Sodium | Montelukast Sodium | 515 | 151 |
| Gabapentin | Gabapentin | 513 | 136 |
| Alendronate Sodium | Alendronate Sodium | 469 | 138 |
| Omeprazole | Omeprazole | 453 | 122 |
| Metformin Hcl Er | Metformin Hcl | 407 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 96 |
| Simvastatin | Simvastatin | 360 | 96 |
| Furosemide | Furosemide | 343 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 305 | 100 |
| Fluticasone Propionate | Fluticasone Propionate | 305 | 119 |
| Trulicity | Dulaglutide | 284 | 59 |
| Losartan Potassium | Losartan Potassium | 277 | 77 |
| Celecoxib | Celecoxib | 274 | 93 |
| Eliquis | Apixaban | 263 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 251 | 71 |
| Sertraline Hcl | Sertraline Hcl | 251 | 62 |
| Trazodone Hcl | Trazodone Hcl | 248 | 63 |
| Famotidine | Famotidine | 239 | 65 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 239 | 77 |
| Buspirone Hcl | Buspirone Hcl | 229 | 60 |
| Ozempic | Semaglutide | 223 | 50 |
| Rybelsus | Semaglutide | 223 | 58 |
| Jardiance | Empagliflozin | 222 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 55 |
| Meclizine Hcl | Meclizine Hcl | 198 | 63 |
| Irbesartan | Irbesartan | 196 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 195 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 187 | 51 |
| Donepezil Hcl | Donepezil Hcl | 178 | 46 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 177 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 62 |
| Repaglinide | Repaglinide | 172 | 49 |
| Farxiga | Dapagliflozin Propanediol | 171 | 41 |
| Mirtazapine | Mirtazapine | 166 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 46 |
| Valsartan | Valsartan | 152 | 38 |
| Lorazepam | Lorazepam | 151 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 33 |
| Pregabalin | Pregabalin | 147 | 45 |
| Januvia | Sitagliptin Phosphate | 146 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 145 | 32 |
| Linzess | Linaclotide | 145 | 45 |
| Metformin Hcl | Metformin Hcl | 145 | 43 |
| Potassium Chloride | Potassium Chloride | 135 | 38 |
| Allopurinol | Allopurinol | 134 | 39 |
| Nifedipine Er | Nifedipine | 130 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 34 |
| Topiramate | Topiramate | 123 | 35 |
| Fenofibrate | Fenofibrate,micronized | 122 | 37 |
| Clonazepam | Clonazepam | 117 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 28 |
| Entresto | Sacubitril/Valsartan | 108 | 16 |
| Atenolol | Atenolol | 106 | 26 |
| Ezetimibe | Ezetimibe | 103 | 32 |
| Xarelto | Rivaroxaban | 99 | 19 |
| Glimepiride | Glimepiride | 97 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 23 |
| Prednisone | Prednisone | 90 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 43 |
| Spironolactone | Spironolactone | 88 | 26 |
| Ibuprofen | Ibuprofen | 87 | 37 |
| Terazosin Hcl | Terazosin Hcl | 85 | 26 |
| Ketoconazole | Ketoconazole | 82 | 39 |
| Tradjenta | Linagliptin | 81 | 16 |
| Carvedilol | Carvedilol | 79 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 16 |
| Nystatin | Nystatin | 78 | 54 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 22 |
| Nitroglycerin | Nitroglycerin | 74 | 47 |
| Metoclopramide Hcl | Metoclopramide Hcl | 73 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 26 |
| Bupropion Xl | Bupropion Hcl | 69 | 14 |
| Lamotrigine | Lamotrigine | 69 | 15 |
| Memantine Hcl | Memantine Hcl | 69 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 15 |
| Mounjaro | Tirzepatide | 68 | 15 |
| Alprazolam | Alprazolam | 66 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 66 | 16 |
| Chlorthalidone | Chlorthalidone | 65 | 20 |
| Primidone | Primidone | 65 | 11 |
| Propranolol Hcl | Propranolol Hcl | 64 | 12 |
| Methylprednisolone | Methylprednisolone | 63 | 55 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 14 |
| Hydrocortisone | Hydrocortisone | 58 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 15 |
| Azithromycin | Azithromycin | 56 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 19 |
| Livalo | Pitavastatin Calcium | 54 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 11 |
| Lidocaine | Lidocaine | 52 | 24 |
| Tramadol Hcl | Tramadol Hcl | 52 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 51 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 49 | 16 |
| Azelastine Hcl | Azelastine Hcl | 47 | 34 |
| Finasteride | Finasteride | 47 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 46 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 35 |
| Acamprosate Calcium | Acamprosate Calcium | 44 | 17 |
| Ondansetron Odt | Ondansetron | 43 | 24 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Clotrimazole | Clotrimazole | 40 | 29 |
| Aripiprazole | Aripiprazole | 39 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Calcitriol | Calcitriol | 38 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 35 | 15 |
| Torsemide | Torsemide | 35 | 12 |
| Sucralfate | Sucralfate | 34 | suppressed |
| Colchicine | Colchicine | 33 | 13 |
| Levofloxacin | Levofloxacin | 33 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 25 |
| Mometasone Furoate | Mometasone Furoate | 31 | 15 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Naproxen | Naproxen | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 14 |
| Mupirocin | Mupirocin | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Austedo | Deutetrabenazine | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 16 |
| Cephalexin | Cephalexin | 19 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,339.62 · 101 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, LAGEVRIO, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error